Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?

被引:2
作者
Cerovac, S
Mashhadi, SA
Williams, AM
Allan, RA
Stanley, PRW
Powell, BWEM
机构
[1] UCH London, Royal Free Hosp London, Surrey CRO 5RA, England
[2] Castle Hill Hosp, Cottingham HU16 5JQ, E Yorkshire, England
[3] St George Hosp, London SW17 0QT, England
关键词
melanoma; recurrence; local; in-transit; sentinel lymph node biopsy;
D O I
10.1016/j.bjps.2005.12.002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Recent publications have suggested that sentinel lymph node biopsy (SLNB) and completion lymphadenectomy (CLND) increase the rate of local and in-transit disease up to 23% in sentinel node positive group of patients with cutaneous melanoma. This retrospective study combined the data from two national centres on local and in-transit disease in 972 melanoma patients who underwent SLNB procedure over 6.5 years period. In total, 77 patients (7.9%) developed loco-regional recurrence: 41 (4.2%) local recurrence only and 36 patients (3.7%) in-transit metastases during a mean follow-up of 42 months. Patients with positive sentinel lymph node were three times more likely to develop loco-regional metastases than those with no nodal disease (17 vs. 5.6%). Over one third of all recurrences developed following excision of thick (Breslow thickness over 4 mm) primary tumours. In both centres age and Breslow thickness were found to be significantly higher in the recurrence group (p<0.001 for both). This study revealed a strong association between increased risk of loco-regional. metastases and aggressive tumour biology and adverse patients factors. No conclusive evidence was found to support an increased incidence in patients undergoing SLNB and CLND compared to that published for patients undergoing wide local excision alone. (C) 2006 The British Association of Plastic Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 30 条
[1]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[2]   Are locoregional cutaneous metastases in melanoma predictable? [J].
Borgstein, PJ ;
Meijer, S ;
van Diest, PJ .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (03) :315-321
[3]  
CALABRO A, 1989, ARCH SURG-CHICAGO, V124, P1051
[4]  
Cascinelli N, 1998, SEMIN SURG ONCOL, V14, P272, DOI 10.1002/(SICI)1098-2388(199806)14:4<272::AID-SSU2>3.0.CO
[5]  
2-#
[6]   Patterns of early recurrence after sentinel lymph node biopsy for melanoma [J].
Chao, C ;
Wong, SL ;
Ross, MI ;
Reintgen, DS ;
Noyes, RD ;
Cerrito, PB ;
Edwards, MJ ;
McMasters, KM .
AMERICAN JOURNAL OF SURGERY, 2002, 184 (06) :520-524
[7]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[8]  
Clifford E, 2002, AM J SURG, V184, P525
[9]  
Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO
[10]  
2-D